Dominic Vacchiano’s Post

💰 Biotech Early Round Funding Activity ($1M+) - 1H 2024 We analyzed early-round biotech funding data from our online BiopharmIQ platform. See the recent funding activity: https://lnkd.in/g6rEmde3 Early round = Angel/pre-Seed, Seed, Series A 1st half 2024 Not surprisingly: ⇒ U.S. was at the top of the list (29 companies). Surprising? ⇒ UK (9 co) and China (9 co) had almost 1/3 as many companies as U.S. ⇒ Switzerland (7 co) was next on the list. ⇒ Canada (4 co) had twice as many companies as France (2 co). ⇒ Germany has 0 companies. For more details and more graphical data, see our blog post https://lnkd.in/giriKX84 Have questions or want to schedule an online demo? Contact marketing@biopharmiq.com

Interesting to see the countries with private companies with early stage funding of at least $1M captured by our BiopharmIQ systems for the 1st half of 2024. It will be interesting to see if this activity in the U.S. picks up in Q3 and Q4, from tailwinds provided by a hopefully favorable environment for public smid-cap biopharma stocks (decreasing interest rate environment & hopefully not too negative on bio/pharma Tx pricing into and after U.S. elections). Of course, some high profile biotech M&A should help biotech funding overall. Just not certain that a positive overall public biotech market, especially small & mid-cap biotech market, will pull through to private early-stage funding. Surprising that there were 0 biotech companies in Germany identified by our BiopharmIQ systems that received $1M or more in early stage funding. And surprised to see twice as many of these early-funded companies in Canada as France. Of course, once we have data for the full year, things might balance out more toward expectations.

#Biotech funding is a hot topic! This week, Mediar CEO Rahul Ballal, PhD, will share his perspectives during two panel discussions. First up this afternoon is "Fueling the Future: CEO Perspectives on Funding Clinical-Stage Biotechs" with Clinical Outsourcing Group New England, a conversation with biotech leaders about strategies for financing clinical pipelines, including international trends in venture capital, public markets, licensing deals, local government funding, and cross-border partnerships. Rounding out the week on Thursday is "Cautious Optimism? State of Biotech Funding in 2024" at MassBio Align Summit, discussing the evolving opportunities and headwinds across the funding landscape, how to effectively respond to challenges, and ways to capitalize on market trends to support innovations We look forward to sharing our insights and connecting with other #biotech pioneers for these important discussions. #COGNewEngland #AlignSummit24

Biotech funding categorised by area and investors 👇 Amid the challenges of 2023, 𝐚 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐭𝐫𝐞𝐧𝐝 𝐩𝐞𝐫𝐬𝐢𝐬𝐭𝐞𝐝, proving instrumental for start-ups in securing vital funding – the emphasis on advancing into clinical stages. A lot of Series A-C rounds secured. 𝐃𝐚𝐭𝐚 𝐡𝐨𝐥𝐝𝐬 𝐭𝐡𝐞 𝐤𝐞𝐲. Strong clinical results have a competitive edge, attracting investors interested in promising advancements. ➡️ In Phase 2 clinical trials, the importance of data and compelling clinical results cannot be overstated. Positive outcomes not only affirm the treatment's potential but also wield a pivotal influence on the trajectory of the biotech company, shaping investor interest, fostering partnerships and guiding future development strategies. 𝐇𝐨𝐰 𝐝𝐨 𝐲𝐨𝐮 𝐬𝐞𝐞 𝐕𝐂 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 𝐩𝐥𝐚𝐲𝐢𝐧𝐠 𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐲𝐞𝐚𝐫? (Source: Oppenheimer & Co. Inc. and PitchBook). 🚨 Make sure to follow the hashtag #CGTweekly to be instantly updated on ALL news as well as infographics and trends. #biotech #celltherapy #genetherapy

👉 Watch our latest BaseLaunch video, "Key Strategies for biotech companies transitioning from early- to late-stage." This video features expert insights from Peter Mozerov, Senior Manager of Life Science Strategy at KPMG Switzerland, interviewed by Martyna Wroblewska on how biotech founders and CEOs can successfully manage the complex process of moving from early-stage development to commercialization.   In this interview, we discuss key topics like building a strong foundation, designing a flexible structure to attract investors, and preparing for long-term growth.    👉 Watch the full interview below 👉 Read more: https://lnkd.in/dzGNsmnD   Stephan Emmerth, Neil Goldsmith, Virginia Ballotta, Lenka Michalkova #AccelerateInBasel #Therapeutics #Biotech #Innovation

🧬🧬 𝑴𝒂𝒚𝒃𝒆 𝒔𝒐𝒎𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆 𝒃𝒊𝒐𝒕𝒆𝒄𝒉 𝒏𝒆𝒘𝒔? The Financial Times noted that the US biotech sector is bouncing back, quoting data from Jeffries that shows January’s capital raised ($6.2bn) reached levels similar to the previous high-water mark of February 2021. Overall, the proof of the market’s upturn has solidified the sense of optimism that has been brewing among biotech organisations in recent months and the higher-level narrative is reflecting the same. The optimism isn’t blue-sky naivete, it’s more of a silver lining as biotech companies are aware of the current challenges they still face in the complex and ever-changing development landscape. : https://lnkd.in/g7NGi9pD #bioinformatics #lifescience #software

At the Wellington Management Asia Pacific Investment Forum last week, ClavystBio CEO Khoo Shih sat down with Wellington’s I-hung Shih and Xiaying Zhang, CAIA to discuss the key innovations and trends set to transform the biotech market over the next decade.   Some key takeaways:   1.           Small biotech companies are driving drug discovery The lower cost and faster pace of innovation has opened the gateway for biotechs. Nearly 60% of FDA approvals in the last few years were for therapies originating from small biotechs.   2.           Asia emerges as one of the powerhouses for innovation Beyond the US and Europe, China, Singapore, Japan, Korea and Australia have growing biotech innovations. More than 50% of early-stage ADC deals done last year arose from Asia.   3.           Emphasis on Precision medicine New modalities will fundamentally change the standard of care – not just for personalized treatments but preventive care in the future.     Thank you, Wellington, for the wonderful forum, and insightful discussion! #biotech #precisionmedicine  

Let Venture Capital Firms and NUVISAN Boost Your Drug Discovery Project! Are you working on an orphan disease drug discovery project or tackling challenging targets? This is your opportunity to collaborate with venture capitalists and scientific experts to propel your drug discovery initiative forward. The 2nd NUVISAN Innovation Challenge is seeking groundbreaking ideas in this space to accelerate the development of new treatments for patients in need. 🎯 Theme: Innovative Solutions for Orphan Diseases and Challenging Drug Targets 🎁 Prizes: Winners will have the opportunity to present their ideas to venture capitalists and receive expert scientific consultation from NUVISAN. 🌐 Who Can Apply: Companies worldwide working to address these unmet needs are encouraged to participate. 📅 Submission Deadline: October 29 Explore the event details here: https://lnkd.in/e7skKGDP We look forward to your application! #NUVISAN #ScienceCRO #InnovationChallenge #DrugDiscovery #OrphanDrugs #Biotech #VentureCapital

Happy to echo this urgent call for action by VIB's Jerome Van Biervliet. It's timely and needed to preserve and grow our thriving biotech and life sciences ecosystem in Belgium and beyond. The call for an integrated European Stock Exchange might require a slight nuance. The performance of a US Nasdaq is probably more a result of an integrated US market (opportunity). Only the further streamlining and integration of the European market regulation at all levels will enhance the line of sight on the market opportunity of European biotech developments to investors. This will not only empower already existing (and increasingly integrated) European stock markets (think Euronext), this will also make investments into earlier development more attractive. #MyFiveCents #EU #Biotech #Investing #StockMarket

💰BIO Roundup: Deal-Making Tips And Tricks • WHO SHOULD READ THIS? BD&L professionals in small companies looking for larger partners or investors. • WHAT IS IT? A round-up of insights gathered by Citeline News & Insights reporters from panel discussions and in exclusive interviews at the BIO International Conference on the subject of deal-making. • WHY IS IT IMPORTANT? Biotech companies are competing for the attention of potential partners to fund their R&D and help them achieve commercial success. This feature highlights key advice on decision-making, ranging from pipeline strategy to approaching international markets. Citeline Citeline Commercial #BIO2024